Well-Funded Seres Races To Be First To Market With A Microbiome Drug
This article was originally published in The Pink Sheet Daily
After raising $143 million from an IPO in June, Seres Therapeutics is hoping its lead development candidate SER-109, in Phase II for Clostridium difficile, could be the first microbiome-based drug to reach the market.
You may also be interested in...
As it talks study design with FDA, Seres says new analysis of Phase II trial of microbiome candidate SER-109 suggests that a C. difficile cytotoxin test would be more accurate and that a higher dose may be more effective.
The company’s new CEO Richard Francis is aiming for revenue growth this year; it would be the first time since 2017.
Chief operating officer Stuart Arbuckle and chief scientific officer David Altshuler talked to Scrip about potential launches in sickle cell disease and pain, and the firm’s expanding pipeline.